Osmol is an IND-stage biopharma company based in New Haven, CT, developing technology licensed from Yale School of Medicine to address chemotherapy induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with microtubule-based chemotherapies including taxanes, the most widely used chemotherapy treatment for breast cancer. There are no approved treatments for CIPN, leaving patients' only option to reduce the dose or length of chemo treatment. Osmol’s initial focus is in breast cancer where up to 80% of patients develop CIPN. CIPN is driven by the dysregulation of neuronal calcium sensor-1 (NCS1), a calcium sensor protein that maintains resting calcium concentration and dynamically enhances responses to cellular stimuli. Osmol is developing a novel, patented drug (OSM-0205) to modulate NCS1 function and prevent neuronal damage caused by the off-target effects of chemotherapy. In vivo and in vitro data support the development and effectiveness of OSM-0205 including: characterization of mechanism of efficacy, validation in mouse models of CIPN, and in vivo demonstration of no effect on chemotherapy efficacy. In addition, a limited clinical experience supports the therapeutic hypothesis. Finally, in vivo data support the potential for efficacy in a follow-on indication, chemotherapy-induced cognitive impairment (CICI). Market research with breast cancer specialists at leading US cancer centers confirmed the significant need for effective CIPN treatments that would allow clinicians to provide the optimal planned chemotherapy treatment.